Biomark Diagnostics Inc. (20B.F)

0.1670 -0.0160 (-8.74%) At close: 08:05AM CEST

Biomark Diagnostics Inc.

3851 Shell Road
Suite 130
Richmond, BC V6X 2W2
Canada
604 370 0779
https://www.biomarkdiagnostics.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Rashid Ahmed Maula Bux B.Sc., MBA	Founder, CEO, President & Director	162.94k	N/A	N/A
Ms. Guoyu Huang MBA	Chief Financial Officer	68.03k	N/A	N/A
Mr. Brian Kai-Ming Cheng B.Sc., M.Sc, M.Sc.	Chief Technical Officer & Independent Director	N/A	N/A	N/A
Dr. Jeff Haince Ph.D.	GM & Chief Scientific Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It holds an agreement with National Research Council of Canada Industrial Research Assistance Program to support research and development of liquid biopsy assay for the early detection and screening of lung cancer; and strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. operates as a subsidiary of Biomark Technologies Inc.

Corporate Governance

Biomark Diagnostics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.